Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

RICHMOND, Calif., Aug. 26, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.  Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

"Ceregene is a leader in development and manufacturing of AAV-based therapies with significant clinical development experience," said Edward Lanphier, Sangamo's president and CEO.  "Since their inception in 2001, the company has safely treated over 115 subjects in four clinical trials. Sangamo has acquired all of Ceregene's AAV assets including CERE-110, AAV delivery of nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease.  CERE-110 is being evaluated in a fully enrolled and fully funded Phase 2 clinical trial. In addition to the AAV platform, the assets also include one of the world's largest databases of AAV GMP manufacturing know-how, toxicology data, and safety data from their human clinical trials, which will be an invaluable resource as we advance our ZFP Therapeutics."

Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, which represents less than 0.2 percent of Sangamo's total shares outstanding.  In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene.  The acquisition is
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they will ... Senior Living Community in Palatine, IL. The group, called “New ... Wednesdays of every month. This group will begin on ... 55 S. Greeley St. Palatine, IL 60067. It is ... for the group. , “A grief support group is ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... cholesterol higher than national guidelines recommend that, if managed, ... a study published in the issue of Neurology, the ... ,The study of 1,040 people hospitalized for ... percent had cholesterol higher than recommended by national guidelines. ...
... the risk of becoming infected with tuberculosis (TB) and ... according to an analysis of previously published in issue ... the world’s population is infected with the bacteria that ... inactive by the immune system, according to background information ...
... Phase 3 study of the drug Vandetanib, marketed by London ... study will cover 508 patients of lung cancer in whom ... countries and 20 sites. , The patients who ... non-small cell lung cancer will be given the once-daily drug ...
... Ruby has been diagnosed with a brain tumor which is at ... led her parents// to approach the doctor who after routine tests ... The doctors have given her three to six months of life ... week course of radiation which is expected to reduce the size ...
... be able to provide ‘safe prawns’ for seafood allergy ... these prawns without the fear of an adverse reaction. ... removing from prawns the proteins that cause an allergic ... in Chemistry & Industry, the magazine of the SCI. ...
... infections such as pneumonia and acute bronchitis, says a ... of hospitalisation. ,Rhinoviruses are among the ... least 50 percent of all common colds. ... illnesses in children is increasingly accepted and has been ...
Cached Medicine News:Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Susceptibility to TB is High Among the Smokers 2Health News:Common Cold may Cause Severe Respiratory Infection 2
... With the ProtecPoint Exit Alerting System, ... staff) and assets (e.g. medical equipment), ... your facility. With this form of ... cost savings, operating efficiencies, and overall ...
... Context-sensitive medicine is the ability of medical ... pre-determined ways based on what is happening ... associations a Radianse indoor positioning solution (IPS) ... it requires identity, location and time to ...
... the movement of controlled substances, critical ... done. VerdaSee's "intellishelvess" are designed to ... is possible with no human intervention. ... this possible. VerdaSee Intellishelf™ product solutions ...
Agility has delivered a RFID-enabled mobile asset management program....
Medicine Products: